DTIL earnings analysis
What we found in DTIL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Precision BioSciences reported a significant increase in Q1 2026 revenue to $10.8 million, surpassing expectations of $4.78 million and marking a leap from a mere $29,000 in Q1 2025. Operating expenses decreased, resulting in a reduced net loss of $18.4 million, compared to $20.6 million a year prior. The firm maintains a robust cash position of $125.8 million, with sufficient runway to fund operations through 2028, despite ongoing losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Surges to $10.8M
- Revenue jumped to $10.8 million, up from $29,000 in Q1 2025, benefiting from licensing agreements.
- Narrowed Net Loss
- Net loss decreased to $18.4 million from $20.6 million year-over-year, reflecting stronger financial management.
- Improved Cash Position
- Cash and cash equivalents increased to $125.8 million from $99.8 million year-over-year, providing substantial operational runway.
- R&D Spending Stability
- Research and development costs remained stable at $13.1 million, showing effective cost management amid expansion.
- Successful Collaboration Update
- The company announced acceptance of a late-breaking poster on PBGENE-HBV at a major medical conference.
- Regulatory Approval Progress
- PBGENE-DMD received FDA Fast Track designation, potentially expediting development.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Losses
- Despite lower losses, Q1 2026 reported $18.4 million loss, emphasizing ongoing financial challenges.
- Heavy Dependence on Third-Party Collaborations
- Future success hinges on third-party performance, which could disrupt timelines if mismanaged.
- Failure to Meet Nasdaq Requirements
- Past non-compliance with Nasdaq listing standards may impact stock performance and investor sentiment.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.75
What they said about what is next.
Expecting sufficient cash runway through 2028 to fund research and operations.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DTIL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever